Sergi Ferre

List of Publications by Year
in descending order

285 papers	22,353 citations	5896 81 h-index	11308 136 g-index
287 all docs	287 docs citations	287 times ranked	11492 citing authors

#	Article	IF	Citations
1	Adenosineâ€“dopamine receptorâ€“receptor interactions as an integrative mechanism in the basal ganglia. Trends in Neurosciences, 1997, 20, 482-487.	8.6	758
2	Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A1-A2A Receptor Heteromers. Journal of Neuroscience, 2006, 26, 2080-2087.	3.6	553
3	Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 7238-7241.	7.1	499
4	G Proteinâ€“Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives. Pharmacological Reviews, 2014, 66, 413-434.	16.0	497
5	Coaggregation, Cointernalization, and Codesensitization of Adenosine A2A Receptors and Dopamine D2Receptors. Journal of Biological Chemistry, 2002, 277, 18091-18097.	3.4	450
6	Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 8606-8611.	7.1	419
7	Adenosine A2A-Dopamine D2 Receptor-Receptor Heteromerization. Journal of Biological Chemistry, 2003, 278, 46741-46749.	3.4	401
8	An update on the mechanisms of the psychostimulant effects of caffeine. Journal of Neurochemistry, 2008, 105, 1067-1079.	3.9	368
9	Adenosine-dopamine interactions in the brain. Neuroscience, 1992, 51, 501-512.	2.3	350
10	Building a new conceptual framework for receptor heteromers. Nature Chemical Biology, 2009, 5, 131-134.	8.0	349
11	Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: Implications for striatal neuronal function. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11940-11945.	7.1	345
12	Adenosine A2A receptors and basal ganglia physiology. Progress in Neurobiology, 2007, 83, 277-292.	5.7	336
13	Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons. Pharmacological Reviews, 2003, 55, 509-550.	16.0	306
14	Caffeine Induces Dopamine and Glutamate Release in the Shell of the Nucleus Accumbens. Journal of Neuroscience, 2002, 22, 6321-6324.	3.6	279
15	Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nature Methods, 2008, 5, 727-733.	19.0	269
16	Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. Journal of Neural Transmission, 1993, 93, 11-25.	2.8	268
17	Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia1Published on the World Wide Web on 12 January 1998.1. Brain Research Reviews, 1998, 26, 258-273.	9.0	266
18	Metabotropic glutamate type 5, dopamine D₂ and adenosine A_{2a} receptors form higherâ€order oligomers in living cells. Journal of Neurochemistry, 2009, 109, 1497-1507.	3.9	249

#	ARTICLE	IF	CITATIONS
19	Adenosine receptorâ€“dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiology and Behavior, 2007, 92, 210-217.	2.1	239
20	Amazing Stability of the Arginineâˆ'Phosphate Electrostatic Interaction. Journal of Proteome Research, 2005, 4, 1397-1402.	3.7	233
21	Striatal Adenosine A2A and Cannabinoid CB1 Receptors Form Functional Heteromeric Complexes that Mediate the Motor Effects of Cannabinoids. Neuropsychopharmacology, 2007, 32, 2249-2259.	5.4	229
22	An Update on Adenosine A2A-Dopamine D2 Receptor Interactions: Implications for the Function of G Protein-Coupled Receptors. Current Pharmaceutical Design, 2008, 14, 1468-1474.	1.9	229
23	Adenosine-dopamine interactions in the ventral striatum. Psychopharmacology, 1997, 133, 107-120.	3.1	222
24	Identification of Dopamine D1â€“D3 Receptor Heteromers. Journal of Biological Chemistry, 2008, 283, 26016-26025.	3.4	216
25	Adenosine A_{2A} and Dopamine D₂ Heteromeric Receptor Complexes and Their Function. Journal of Molecular Neuroscience, 2005, 26, 209-220.	2.3	207
26	Evidence That Sleep Deprivation Downregulates Dopamine D2R in Ventral Striatum in the Human Brain. Journal of Neuroscience, 2012, 32, 6711-6717.	3.6	203
27	Combining Mass Spectrometry and Pull-Down Techniques for the Study of Receptor Heteromerization. Direct Epitopeâˆ'Epitope Electrostatic Interactions between Adenosine A2Aand Dopamine D2Receptors. Analytical Chemistry, 2004, 76, 5354-5363.	6.5	195
28	Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders. Current Pharmaceutical Design, 2008, 14, 1512-1524.	1.9	181
29	Involvement of Adenosine A1 and A2A Receptors in the Motor Effects of Caffeine after its Acute and Chronic Administration. Neuropsychopharmacology, 2003, 28, 1281-1291.	5.4	177
30	Dopamine D2 and Adenosine A2A Receptors Regulate NMDA-Mediated Excitation in Accumbens Neurons Through A2Aâ€“D2 Receptor Heteromerization. Neuropsychopharmacology, 2009, 34, 972-986.	5.4	174
31	Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience, 1994, 63, 765-773.	2.3	170
32	Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease. , 2011, 132, 280-299.		170
33	Sleep Deprivation Decreases Binding of [¹¹C]Raclopride to Dopamine D₂/D₃Receptors in the Human Brain. Journal of Neuroscience, 2008, 28, 8454-8461.	3.6	168
34	Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology, 2008, 55, 190-197.	4.1	157
35	Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. Journal of Neurochemistry, 2005, 93, 762-765.	3.9	153
36	Direct involvement of Ïƒ-1 receptors in the dopamine D ₁ receptor-mediated effects of cocaine. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18676-18681.	7.1	153

#	Article	IF	Citations
37	Adenosine A2A Agonists: A Potential New Type of Atypical Antipsychotic. Neuropsychopharmacology, 1997, 17, 82-91.	5.4	149
38	Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders. Psychopharmacology, 2016, 233, 1963-1979.	3.1	149
39	Evidence for Adenosine/Dopamine Receptor Interactions Indications for Heteromerization. Neuropsychopharmacology, 2000, 23, S50-S59.	5.4	147
40	Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. Journal of Neurochemistry, 2003, 88, 726-734.	3.9	139
41	Marked changes in signal transduction upon heteromerization of dopamine D₁ and histamine H₃ receptors. British Journal of Pharmacology, 2009, 157, 64-75.	5.4	138
42	Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends in Neurosciences, 2007, 30, 440-446.	8.6	136
43	Allosteric interactions between agonists and antagonists within the adenosine A _{2A} receptor-dopamine D ₂ receptor heterotetramer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3609-18.	7.1	135
44	Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Frontiers in Bioscience - Landmark, 2008, 13, 2391.	3.0	135
45	Dopamine D1Receptor-mediated Facilitation of GABAergic Neurotransmission in the Rat Strioentopeduncular Pathway and its Modulation by Adenosine A1Receptor-mediated Mechanisms. European Journal of Neuroscience, 1996, 8, 1545-1553.	2.6	134
46	Opposite modulatory roles for adenosine A₁and A_{2A}receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. Journal of Neurochemistry, 2004, 88, 1151-1158.	3.9	134
47	Postsynaptic antagonistic interaction between adenosine A1, and dopamine D1 receptors. NeuroReport, 1994, 6, 73-76.	1.2	133
48	Adenosine A2A-dopamine D2 receptorâ€“receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism and Related Disorders, 2004, 10, 265-271.	2.2	132
49	Circadian-Related Heteromerization of Adrenergic and Dopamine D4 Receptors Modulates Melatonin Synthesis and Release in the Pineal Gland. PLoS Biology, 2012, 10, e1001347.	5.6	132
50	The Selective mGlu5 Receptor Agonist CHPG Inhibits Quinpirole-Induced Turning in 6-Hydroxydopamine-Lesioned Rats and Modulates the Binding Characteristics of Dopamine D2 Receptors in the Rat Striatum Interactions with Adenosine A2a Receptors. Neuropsychopharmacology, 2001, 25, 505-513.	5.4	130
51	Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry. Progress in Neurobiology, 2007, 83, 332-347.	5.7	130
52	Personality traits and vulnerability or resilience to substance use disorders. Trends in Cognitive Sciences, 2014, 18, 211-217.	7.8	126
53	Receptor-receptor interactions as an integrative mechanism in nerve cells. Molecular Neurobiology, 1993, 7, 293-334.	4.0	124
54	Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A2A and dopamine D2 receptors. Neuroscience Letters, 2002, 324, 154-158.	2.1	124

#	Article	IF	Citations
55	Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism and Related Disorders, 2001, 7, 235-241.	2.2	118
56	Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain. Neurobiology of Learning and Memory, 2007, 87, 42-56.	1.9	115
57	Striatal Pre- and Postsynaptic Profile of Adenosine A2A Receptor Antagonists. PLoS ONE, 2011, 6, e16088.	2.5	115
58	Functional Selectivity of Allosteric Interactions within G Proteinâ€"Coupled Receptor Oligomers: The Dopamine D₁-D₃ Receptor Heterotetramer. Molecular Pharmacology, 2014, 86, 417-429.	2.3	114
59	Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors. Biochemical Pharmacology, 1999, 58, 1035-1045.	4.4	113
60	Intramembrane receptorâ€"receptor interactions: a novel principle in molecular medicine. Journal of Neural Transmission, 2007, 114, 49-75.	2.8	113
61	Adenosineâ€"cannabinoid receptor interactions. Implications for striatal function. British Journal of Pharmacology, 2010, 160, 443-453.	5.4	113
62	Neurotransmitter receptor heteromers and their integrative role in â€˜local modulesâ€™: The striatal spine module. Brain Research Reviews, 2007, 55, 55-67.	9.0	112
63	Cocaine Inhibits Dopamine D2 Receptor Signaling via Sigma-1-D2 Receptor Heteromers. PLoS ONE, 2013, 8, e61245.	2.5	112
64	Dopamine D1-histamine H3 Receptor Heteromers Provide a Selective Link to MAPK Signaling in GABAergic Neurons of the Direct Striatal Pathway. Journal of Biological Chemistry, 2011, 286, 5846-5854.	3.4	109
65	Stimulation of adenosine A2 receptors induces catalepsy. Neuroscience Letters, 1991, 130, 162-164.	2.1	108
66	Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-d-aspartate receptor stimulation. Journal of Neurochemistry, 2004, 91, 873-880.	3.9	107
67	The GPCR heterotetramer: challenging classical pharmacology. Trends in Pharmacological Sciences, 2015, 36, 145-152.	8.7	106
68	Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain. Translational Psychiatry, 2015, 5, e549-e549.	4.8	106
69	Differential glutamate-dependent and glutamate-independent adenosine A1receptor-mediated modulation of dopamine release in different striatal compartments. Journal of Neurochemistry, 2007, 101, 355-363.	3.9	104
70	Dopamine denervation leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum. Brain Research, 1992, 594, 124-130.	2.2	103
71	Role of the Central Ascending Neurotransmitter Systems in the Psychostimulant Effects of Caffeine. Journal of Alzheimer's Disease, 2010, 20, S35-S49.	2.6	103
72	Evidence for functional pre-coupled complexes of receptor heteromers and adenylyl cyclase. Nature Communications, 2018, 9, 1242.	12.8	103

#	Article	IF	Citations
73	Interactions between Intracellular Domains as Key Determinants of the Quaternary Structure and Function of Receptor Heteromers. Journal of Biological Chemistry, 2010, 285, 27346-27359.	3.4	102
74	Adenosine A1 Receptor-mediated Modulation of Dopamine D1 Receptors in Stably Cotransfected Fibroblast Cells. Journal of Biological Chemistry, 1998, 273, 4718-4724.	3.4	98
75	Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice. European Journal of Pharmacology, 1991, 192, 31-37.	3.5	95
76	Postsynaptic dopamine/adenosine interaction: I. Adenosine analogues inhibit dopamine D2-mediated behaviour in short-term reserpinized mice. European Journal of Pharmacology, 1991, 192, 25-30.	3.5	94
77	Adenosine A2A receptors modulate the binding characteristics of dopamine D2 receptors in stably cotransfected fibroblast cells. European Journal of Pharmacology, 1996, 316, 325-331.	3.5	91
78	Adenosine Receptor Heteromers and their Integrative Role in Striatal Function. Scientific World Journal, The, 2007, 7, 74-85.	2.1	89
79	Heterodimeric adenosine receptors: a device to regulate neurotransmitter release. Cellular and Molecular Life Sciences, 2006, 63, 2427-2431.	5.4	88
80	Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A₁ and A_{2A} subtype receptor agonists. British Journal of Pharmacology, 2005, 144, 642-650.	5.4	87
81	Key Modulatory Role of Presynaptic Adenosine A_{2A}Receptors in Cortical Neurotransmission to the Striatal Direct Pathway. Scientific World Journal, The, 2009, 9, 1321-1344.	2.1	86
82	Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. Nature Neuroscience, 2013, 16, 1652-1661.	14.8	85
83	New Insights into the Neurobiology of Restless Legs Syndrome. Neuroscientist, 2019, 25, 113-125.	3.5	85
84	GPCR homomers and heteromers: A better choice as targets for drug development than GPCR monomers?. , 2009, 124, 248-257.		84
85	Basic Concepts in G-Protein-Coupled Receptor Homo- and Heterodimerization. Scientific World Journal, The, 2007, 7, 48-57.	2.1	83
86	Adenosine A2A and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D2 receptors in the rat striatum. Neuropharmacology, 1999, 38, 129-140.	4.1	82
87	Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2Areceptors in dopamine D2receptor regulation in the rat dopamine-denervated striatum. European Journal of Neuroscience, 2000, 12, 4033-4037.	2.6	82
88	Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology, 2009, 56, 226-234.	4.1	82
89	Dopamine D4 receptor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain. Molecular Psychiatry, 2012, 17, 650-662.	7.9	82
90	Blocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia Disorders. Recent Patents on CNS Drug Discovery, 2007, 2, 1-21.	0.9	79

#	Article	IF	Citations
91	Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum. NeuroReport, 2001, 12, 1831-1834.	1.2	78
92	Differential effects of selective adenosine A1 and A2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. European Journal of Pharmacology, 1998, 347, 153-158.	3.5	77
93	Allosteric mechanisms within the adenosine A2Aâ€“dopamine D2 receptor heterotetramer. Neuropharmacology, 2016, 104, 154-160.	4.1	77
94	Dopamine D₂ Receptorâ€Mediated Regulation of Serotonin Extracellular Concentration in the Dorsal Raphe Nucleus of Freely Moving Rats. Journal of Neurochemistry, 1993, 61, 772-775.	3.9	76
95	The Two-State Dimer Receptor Model: A General Model for Receptor Dimers. Molecular Pharmacology, 2006, 69, 1905-1912.	2.3	76
96	Is experimental catalepsy properly measured?. Pharmacology Biochemistry and Behavior, 1990, 35, 753-757.	2.9	75
97	Regulation of heptaspanning-membrane-receptor function by dimerization and clustering. Trends in Biochemical Sciences, 2003, 28, 238-243.	7.5	74
98	Role of Electrostatic Interaction in Receptorâ€“Receptor Heteromerization. Journal of Molecular Neuroscience, 2005, 26, 125-132.	2.3	74
99	Essential Control of the Function of the Striatopallidal Neuron by Pre-coupled Complexes of Adenosine A2A-Dopamine D2 Receptor Heterotetramers and Adenylyl Cyclase. Frontiers in Pharmacology, 2018, 9, 243.	3.5	73
100	Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease. Parkinsonism and Related Disorders, 2004, 10, 273-280.	2.2	72
101	Receptorâ€“Receptor Interactions, Receptor Mosaics, and Basic Principles of Molecular Network Organization: Possible Implications for Drug Development. Journal of Molecular Neuroscience, 2005, 26, 193-208.	2.3	72
102	Old and new ways to calculate the affinity of agonists and antagonists interacting with G-protein-coupled monomeric and dimeric receptors: The receptorâ€“dimer cooperativity index. , 2007, 116, 343-354.		70
103	Cross-communication between Gi and Gs in a G-protein-coupled receptor heterotetramer guided by a receptor C-terminal domain. BMC Biology, 2018, 16, 24.	3.8	70
104	Adenosine A1 receptor blockade selectively potentiates the motor effects induced by dopamine D1 receptor stimulation in rodents. Neuroscience Letters, 1996, 218, 209-213.	2.1	69
105	Receptorâ€“receptor interactions involving adenosine A1 or dopamine D1 receptors and accessory proteins. Journal of Neural Transmission, 2007, 114, 93-104.	2.8	69
106	Adenosine A1 receptor-dopamine D1 receptor interaction in the rat limbic system: modulation of dopamine D1 receptor antagonist binding sites. Neuroscience Letters, 1996, 208, 109-112.	2.1	67
107	A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors. Psychopharmacology, 2005, 183, 154-162.	3.1	67
108	The Management of Restless Legs Syndrome: An Updated Algorithm. Mayo Clinic Proceedings, 2021, 96, 1921-1937.	3.0	67

#	Article	IF	Citations
109	Activation of Adensine A1 and A2A Receptors Modulates Dopamine D2 Receptor-Induced Responses in Stably Transfected Human Neuroblastoma Cells. Journal of Neurochemistry, 2001, 74, 432-439.	3.9	66
110	Cocaine Disrupts Histamine H₃Receptor Modulation of Dopamine D₁Receptor Signaling: Ïƒ₁-D₁-H₃Receptor Complexes as Key Targets for Reducing Cocaine's Effects. Journal of Neuroscience, 2014, 34, 3545-3558.	3.6	66
111	Orexinâ€“Corticotropin-Releasing Factor Receptor Heteromers in the Ventral Tegmental Area as Targets for Cocaine. Journal of Neuroscience, 2015, 35, 6639-6653.	3.6	66
112	Interactions between Calmodulin, Adenosine A2A, and Dopamine D2 Receptors. Journal of Biological Chemistry, 2009, 284, 28058-28068.	3.4	65
113	Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans. Neuropharmacology, 2013, 67, 476-484.	4.1	64
114	Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome. Frontiers in Neuroscience, 2017, 11, 722.	2.8	64
115	Heteromeric Nicotinic Acetylcholineâ€“Dopamine Autoreceptor Complexes Modulate Striatal Dopamine Release. Neuropsychopharmacology, 2007, 32, 35-42.	5.4	63
116	Adenosine A1 and A2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats. Neuroscience Letters, 1998, 251, 201-204.	2.1	62
117	Evidence for Noncanonical Neurotransmitter Activation: Norepinephrine as a Dopamine D₂-Like Receptor Agonist. Molecular Pharmacology, 2016, 89, 457-466.	2.3	62
118	Dimer-based model for heptaspanning membrane receptors. Trends in Biochemical Sciences, 2005, 30, 360-366.	7.5	60
119	Gâ€proteinâ€coupled receptor heteromers: function and ligand pharmacology. British Journal of Pharmacology, 2008, 153, S90-8.	5.4	60
120	Oligomerization of G-protein-coupled receptors: A reality. Current Opinion in Pharmacology, 2010, 10, 1-5.	3.5	60
121	Alcohol and Caffeine: The Perfect Storm. Journal of Caffeine Research, 2011, 1, 153-162.	0.9	58
122	Involvement of Adenosine A1 and A2A Receptors in the Adenosinergic Modulation of the Discriminative-Stimulus Effects of Cocaine and Methamphetamine in Rats. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 977-986.	2.5	57
123	Molecular mechanisms involved in the adenosine A1 and A2A receptor-induced neuronal differentiation in neuroblastoma cells and striatal primary cultures. Journal of Neurochemistry, 2005, 92, 337-348.	3.9	56
124	How receptor mosaics decode transmitter signals. Possible relevance of cooperativity. Trends in Biochemical Sciences, 2005, 30, 188-193.	7.5	56
125	Interactions among adenosine deaminase, adenosine A1 receptors and dopamine D1 receptors in stably cotransfected fibroblast cells and neurons. Neuroscience, 2002, 113, 709-719.	2.3	55
126	Opposing actions of an adenosine A2 receptor agonist and a GTP analogue on the regulation of dopamine D2 receptors in rat neostriatal membranes. European Journal of Pharmacology, 1993, 244, 311-315.	2.6	53

#	Article	IF	Citations
127	Allosteric Modulation of Dopamine D2Receptors by Homocysteine. Journal of Proteome Research, 2006, 5, 3077-3083.	3.7	53
128	Cortico-striatal circuits: Novel therapeutic targets for substance use disorders. Brain Research, 2015, 1628, 186-198.	2.2	53
129	Targeting hypersensitive corticostriatal terminals in restless legs syndrome. Annals of Neurology, 2017, 82, 951-960.	5.3	52
130	Intracellular Calcium Levels Determine Differential Modulation of Allosteric Interactions within G Protein-Coupled Receptor Heteromers. Chemistry and Biology, 2014, 21, 1546-1556.	6.0	51
131	Control of glutamate release by complexes of adenosine and cannabinoid receptors. BMC Biology, 2020, 18, 9.	3.8	51
132	Antagonistic A2a/D2receptor interactions in the striatum as a basis for adenosine/dopamine interactions in the central nervous system. Drug Development Research, 1993, 28, 374-380.	2.9	50
133	Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist. Addiction Biology, 2011, 16, 405-415.	2.6	50
134	Key role of the dopamine D ₄ receptor in the modulation of corticostriatal glutamatergic neurotransmission. Science Advances, 2017, 3, e1601631.	10.3	48
135	Effect of unilateral nucleus basalis lesion on cortical and striatal acetylcholine and dopamine release monitored in vivo with microdialysis. Neuroscience Letters, 1990, 110, 172-179.	2.1	47
136	G Protein-Coupled Receptor Heteromers as New Targets for Drug Development. Progress in Molecular Biology and Translational Science, 2010, 91, 41-52.	1.7	46
137	Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation. Sleep Medicine, 2017, 31, 71-77.	1.6	46
138	Relationship between rotational behaviour induced by apomorphine and caffeine in rats with unilateral lesion of the nigrostriatal pathway. Neuropharmacology, 1989, 28, 407-409.	4.1	45
139	Enabling role of adenosine A1 receptors in adenosine A2A receptor-mediated striatal expression of c-fos. European Journal of Neuroscience, 2003, 18, 296-302.	2.6	45
140	ROLE OF ADENOSINE IN THE CONTROL OF HOMOSYNAPTIC PLASTICITY IN STRIATAL EXCITATORY SYNAPSES. Journal of Integrative Neuroscience, 2005, 04, 445-464.	1.7	45
141	Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome. Neuropharmacology, 2016, 111, 160-168.	4.1	45
142	Studies on homocysteine plasma levels in Alzheimer?s patients. Relevance for neurodegeneration. Journal of Neural Transmission, 2005, 112, 163-169.	2.8	44
143	Adenosine A2A Receptors and A2A Receptor Heteromers as Key Players in Striatal Function. Frontiers in Neuroanatomy, 2011, 5, 36.	1.7	44
144	Local Control of Extracellular Dopamine Levels in the Medial Nucleus Accumbens by a Glutamatergic Projection from the Infralimbic Cortex. Journal of Neuroscience, 2016, 36, 851-859.	3.6	44

#	Article	IF	Citations
145	Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis. Sleep Medicine, 2018, 45, 94-97.	1.6	44
146	5-HT1B Receptor-Mediated Serotoninergic Modulation of Methylphenidate-Induced Locomotor Activation in Rats. Neuropsychopharmacology, 2008, 33, 619-626.	5.4	43
147	How Calmodulin Interacts with the Adenosine A_{2A} and the Dopamine D₂ Receptors. Journal of Proteome Research, 2008, 7, 3428-3434.	3.7	42
148	Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats. Psychopharmacology, 2005, 179, 576-586.	3.1	41
149	Plasma membrane diffusion of g protein-coupled receptor oligomers. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 2262-2268.	4.1	41
150	Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum. Neuropharmacology, 2011, 61, 967-974.	4.1	41
151	A Significant Role of the Truncated Ghrelin Receptor GHS-R1b in Ghrelin-induced Signaling in Neurons. Journal of Biological Chemistry, 2016, 291, 13048-13062.	3.4	41
152	New Developments on the Adenosine Mechanisms of the Central Effects of Caffeine and Their Implications for Neuropsychiatric Disorders. Journal of Caffeine and Adenosine Research, 2018, 8, 121-130.	0.6	41
153	Opioidâ€“galanin receptor heteromers mediate the dopaminergic effects of opioids. Journal of Clinical Investigation, 2019, 129, 2730-2744.	8.2	41
154	Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism. Neuroscience Letters, 1995, 187, 61-64.	2.1	38
155	Gs-Âversus Golf-dependent functional selectivity mediated by the dopamine D1 receptor. Nature Communications, 2018, 9, 486.	12.8	38
156	Energy gradients for the homeostatic control of brain ECF composition and for VT signal migration: introduction of the tide hypothesis. Journal of Neural Transmission, 2005, 112, 45-63.	2.8	37
157	Light resonance energy transferâ€based methods in the study of G proteinâ€coupled receptor oligomerization. BioEssays, 2008, 30, 82-89.	2.5	37
158	Adenosine A1-Dopamine D1 Receptor Heteromers Control the Excitability of the Spinal Motoneuron. Molecular Neurobiology, 2019, 56, 797-811.	4.0	36
159	Computer-Assisted Image Analysis of Caveolin-1 Involvement in the Internalization Process of Adenosine A_{2A}â€“Dopamine D₂ Receptor Heterodimers. Journal of Molecular Neuroscience, 2005, 26, 177-184.	2.3	35
160	Differential Effects of Presynaptic versus Postsynaptic Adenosine A2A Receptor Blockade on Â9-Tetrahydrocannabinol (THC) Self-Administration in Squirrel Monkeys. Journal of Neuroscience, 2014, 34, 6480-6484.	3.6	35
161	The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease. Journal of Caffeine and Adenosine Research, 2018, 8, 43-58.	0.6	35
162	Effect of N-methyl-d-aspartate on motor activity and in vivo adenosine striatal outflow in the rat. European Journal of Pharmacology, 1999, 385, 15-19.	3.5	34

#	Article	IF	Citations
163	Functional Î¼-Opioid-Galanin Receptor Heteromers in the Ventral Tegmental Area. Journal of Neuroscience, 2017, 37, 1176-1186.	3.6	34
164	In search of alternatives to dopaminergic ligands for the treatment of restless legs syndrome: iron, glutamate, and adenosine. Sleep Medicine, 2017, 31, 86-92.	1.6	34
165	Design of a True Bivalent Ligand with Picomolar Binding Affinity for a G Protein-Coupled Receptor Homodimer. Journal of Medicinal Chemistry, 2018, 61, 9335-9346.	6.4	34
166	Behavioral and cellular dopamine D1 and D3 receptor-mediated synergy: Implications for L-DOPA-induced dyskinesia. Neuropharmacology, 2018, 138, 304-314.	4.1	34
167	Adenosinergic modulation of the discriminative-stimulus effects of methamphetamine in rats. Psychopharmacology, 2002, 161, 348-355.	3.1	33
168	GDNF control of the glutamatergic corticoâ€striatal pathway requires tonic activation of adenosine A_{2A} receptors. Journal of Neurochemistry, 2009, 108, 1208-1219.	3.9	33
169	Biased G Protein-Independent Signaling of Dopamine D1-D3 Receptor Heteromers in the Nucleus Accumbens. Molecular Neurobiology, 2019, 56, 6756-6769.	4.0	33
170	Chronic haloperidol treatment leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum. Psychopharmacology, 1994, 116, 279-284.	3.1	32
171	Motor activation in short- and long-term reserpinized mice: role of , dopamine D1 and dopamine D2 receptors. European Journal of Pharmacology, 1994, 255, 203-213.	3.5	32
172	Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinsonâ€™s disease. Brain Research Bulletin, 2004, 64, 155-164.	3.0	32
173	Novel pharmacological targets based on receptor heteromers. Brain Research Reviews, 2008, 58, 475-482.	9.0	32
174	Effects of chronic caffeine exposure on adenosinergic modulation of the discriminative-stimulus effects of nicotine, methamphetamine, and cocaine in rats. Psychopharmacology, 2009, 203, 355-367.	3.1	31
175	Dopamineâ€“Galanin Receptor Heteromers Modulate Cholinergic Neurotransmission in the Rat Ventral Hippocampus. Journal of Neuroscience, 2011, 31, 7412-7423.	3.6	31
176	Evidence for the heterotetrameric structure of the adenosine A2Aâ€“dopamine D2 receptor complex. Biochemical Society Transactions, 2016, 44, 595-600.	3.4	31
177	Stimulation of adenosine A1receptors attenuates dopamine D1receptor-mediated increase of NGFI-A, c-fos and jun-B mRNA levels in the dopamine-denervated striatum and dopamine D1receptor-mediated turning behaviour. European Journal of Neuroscience, 1999, 11, 3884-3892.	2.6	30
178	On the Molecular Basis of the Receptor Mosaic Hypothesis of the Engram. Cellular and Molecular Neurobiology, 2004, 24, 501-516.	3.3	30
179	Age-related alteration of the adenosine/dopamine balance in the rat striatum. Brain Research, 1998, 795, 297-300.	2.2	29
180	How Proteins Come Together in the Plasma Membrane and Function in Macromolecular Assemblies: Focus on Receptor Mosaics. Journal of Molecular Neuroscience, 2005, 26, 133-154.	2.3	28

#	Article	IF	Citations
181	G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs). , 2022, 231, 107977.		28
182	Up-regulation of striatal adenosine A2A receptors with iron deficiency in rats. Experimental Neurology, 2010, 224, 292-298.	4.1	27
183	Behavioral control by striatal adenosine A_{2A}â€dopamine D₂ receptor heteromers. Genes, Brain and Behavior, 2018, 17, e12432.	2.2	27
184	Theophylline reverses haloperidol-induced catalepsy in the rat possible relevance to the pharmacological treatment of psychosis. Biological Psychiatry, 1988, 24, 642-648.	1.3	26
185	Unilateral neonatal intracerebroventricular 6-hydroxydopamine administration in rats: II. Effects on extracellular monoamine, acetylcholine and adenosine levels monitored with in vivo microdialysis. Psychopharmacology, 1994, 116, 451-456.	3.1	26
186	Dopamine-independent and adenosine-dependent mechanisms involved in the effects of N-methyl-d-aspartate on motor activity in mice. European Journal of Pharmacology, 1995, 275, 171-177.	3.5	26
187	Adenosine and dopamine receptor antagonist binding in the rat ventral and dorsal striatum: lack of changes after a neonatal bilateral lesion of the ventral hippocampus. Neurochemistry International, 1999, 34, 235-244.	3.8	26
188	Î±2A- and Î±2C-Adrenoceptors as Potential Targets for Dopamine and Dopamine Receptor Ligands. Molecular Neurobiology, 2018, 55, 8438-8454.	4.0	26
189	Functional and Neuroprotective Role of Striatal Adenosine A_{2A}Receptor Heterotetramers. Journal of Caffeine and Adenosine Research, 2019, 9, 89-97.	0.6	26
190	Partners for Adenosine A₁ Receptors. Journal of Molecular Neuroscience, 2005, 26, 221-232.	2.3	25
191	Heptaspanning Membrane Receptors and Cytoskeletal/Scaffolding Proteins: Focus on Adenosine, Dopamine, and Metabotropic Glutamate Receptor Function. Journal of Molecular Neuroscience, 2005, 26, 277-292.	2.3	25
192	Blockade of Adenosine A2A Receptors Prevents Protein Phosphorylation in the Striatum Induced by Cortical Stimulation. Journal of Neuroscience, 2006, 26, 10808-10812.	3.6	25
193	Calcium-mediated modulation of the quaternary structure and function of adenosine A2Aâ€“dopamine D2 receptor heteromers. Current Opinion in Pharmacology, 2010, 10, 67-72.	3.5	25
194	Synthesis and Biological Evaluation of a Novel Series of Heterobivalent Muscarinic Ligands Based on Xanomeline and 1-[3-(4-Butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1). Journal of Medicinal Chemistry, 2014, 57, 9065-9077.	6.4	24
195	Prefrontal Cortex-Driven Dopamine Signals in the Striatum Show Unique Spatial and Pharmacological Properties. Journal of Neuroscience, 2020, 40, 7510-7522.	3.6	24
196	Decreased striatal adenosine A2A-dopamine D2 receptor heteromerization in schizophrenia. Neuropsychopharmacology, 2021, 46, 665-672.	5.4	24
197	Paraxanthine displaces the binding of [3H]SCH 23390 from rat striatal membranes. European Journal of Pharmacology, 1990, 179, 295-299.	3.5	23
198	Different Effects of Dopamine Antagonists on Spontaneous and NMDA-Induced Motor Activity in Mice. Pharmacology Biochemistry and Behavior, 1997, 56, 549-553.	2.9	23

#	Article	IF	Citations
199	Prime Time for G-Protein-Coupled Receptor Heteromers as Therapeutic Targets for CNS disorders: The Dopamine D1-D3 Receptor Heteromer. CNS and Neurological Disorders - Drug Targets, 2010, 9, 596-600.	1.4	23
200	Consensus Guidelines on Rodent Models of Restless Legs Syndrome. Movement Disorders, 2021, 36, 558-569.	3.9	23
201	Conditioning of rotational behavior after the administration of a single dose of apomorphine in rats with unilateral denervation of the dopaminergic nigrostriatal pathway: Relevance to drug addiction. Pharmacology Biochemistry and Behavior, 1988, 31, 605-609.	2.9	22
202	A brief appraisal on some aspects of the receptor-receptor interaction. Neurochemistry International, 1995, 27, 139-146.	3.8	22
203	Diminished iron concentrations increase adenosine A2A receptor levels in mouse striatum and cultured human neuroblastoma cells. Experimental Neurology, 2009, 215, 236-242.	4.1	22
204	Fronto-striatal effective connectivity of working memory in adults with cannabis use disorder. Psychiatry Research - Neuroimaging, 2018, 278, 21-34.	1.8	22
205	A Randomized, Placeboâ€Controlled Crossover Study with Dipyridamole for Restless Legs Syndrome. Movement Disorders, 2021, 36, 2387-2392.	3.9	22
206	Neuropharmacology of the adenosine A2A receptors. Drug Development Research, 1996, 39, 450-460.	2.9	21
207	Multiple intramembrane receptorâ€"receptor interactions in the regulation of striatal dopamine D2 receptors. NeuroReport, 1999, 10, 2051-2054.	1.2	21
208	Adenosine as a volume transmission signal. A feedback detector of neuronal activation. Progress in Brain Research, 2000, 125, 353-361.	1.4	21
209	OnÂtheÂNestedÂHierarchicalÂOrganizationÂofÂCNS: Basic Characteristics of Neuronal Molecular Networks. Lecture Notes in Computer Science, 2004, , 24-54.	1.3	21
210	Existence and Theoretical Aspects of Homomeric and Heteromeric Dopamine Receptor Complexes and Their Relevance for Neurological Diseases. NeuroMolecular Medicine, 2005, 7, 061-078.	3.4	21
211	Stimulation of Adenosine Receptors Selectively Activates Gene Expression in Striatal Enkephalinergic Neurons. Neuropsychopharmacology, 2006, 31, 2173-2179.	5.4	21
212	Combined effects of THC and caffeine on working memory in rats. British Journal of Pharmacology, 2012, 165, 2529-2538.	5.4	21
213	Increased Orbitofrontal Brain Activation after Administration of a Selective Adenosine A2A Antagonist in Cocaine Dependent Subjects. Frontiers in Psychiatry, 2012, 3, 44.	2.6	21
214	Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease. Neurobiology of Disease, 2016, 96, 47-53.	4.4	21
215	High-performance liquid chromatographic separation of caffeine, theophylline, theobromine and paraxanthine in rat brain and serum. Biomedical Applications, 1991, 570, 185-190.	1.7	20
216	Stimulation of adenosine A1 receptors prevents the EEG arousal due to dopamine D1 receptor activation in rabbits. European Journal of Pharmacology, 1996, 305, 123-126.	3.5	20

#	Article	IF	Citations
217	Caffeine and Substance Use Disorders. Journal of Caffeine Research, 2013, 3, 57-58.	0.9	20
218	Role of placebo effects in pain and neuropsychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 87, 298-306.	4.8	20
219	Astrocytic Mechanisms Involving Kynurenic Acid Control Î”9-Tetrahydrocannabinol-Induced Increases in Glutamate Release in Brain Reward-Processing Areas. Molecular Neurobiology, 2019, 56, 3563-3575.	4.0	20
220	Oligomerization of G protein-coupled receptors: Still doubted?. Progress in Molecular Biology and Translational Science, 2020, 169, 297-321.	1.7	20
221	Modulation of dopamine D1 receptors via histamine H3 receptors is a novel therapeutic target for Huntington's disease. ELife, 2020, 9, .	6.0	20
222	Serotonergic agonists behave as partial agonists at the dopamine D2 receptor. NeuroReport, 1999, 10, 493-495.	1.2	19
223	GABA-dopamine receptor-receptor interactions in neostriatal membranes of the rat. Neurochemical Research, 1997, 22, 1051-1054.	3.3	18
224	Glutamate mGlu5-Adenosine A2A-Dopamine D2 Receptor Interactions in the Striatum. Implications for Drug Therapy in Neuro-psychiatric Disorders and Drug Abuse. Current Medicinal Chemistry - Central Nervous System Agents, 2003, 3, 1-26.	0.5	18
225	Rotational behaviour induced by theophylline in 6-OHDA nigrostriatal denervated rats is dependent on the supersensitivity of striatal dopaminergic receptors. Pharmacology Biochemistry and Behavior, 1989, 33, 609-613.	2.9	17
226	Local Dopaminergic Modulation of the Motor Activity Induced by N-methyl-D-aspartate Receptor Stimulation in the Ventral Hippocampus. Neuropsychopharmacology, 2002, 26, 737-743.	5.4	17
227	Comparison between apomorphine and amphetamine-induced rotational behaviour in rats with a unilateral nigrostriatal pathway lesion. Neuropharmacology, 1988, 27, 657-659.	4.1	16
228	Brain-iron deficiency models of restless legs syndrome. Experimental Neurology, 2022, 356, 114158.	4.1	16
229	Functional changes in postsynaptic adenosine A2A receptors during early stages of a rat model of Huntington disease. Experimental Neurology, 2011, 232, 76-80.	4.1	15
230	Adenosine mechanisms and hypersensitive corticostriatal terminals in restless legs syndrome. Rationale for the use of inhibitors of adenosine transport. Advances in Pharmacology, 2019, 84, 3-19.	2.0	15
231	Reinterpreting anomalous competitive binding experiments within G protein-coupled receptor homodimers using a dimer receptor model. Pharmacological Research, 2019, 139, 337-347.	7.1	15
232	Effects of the systemic administration of kainic acid and NMDA on exploratory activity in rats. Pharmacology Biochemistry and Behavior, 1995, 51, 205-210.	2.9	14
233	Development of novel biosensors to study receptor-mediated activation of the G-protein Î± subunits Gs and Golf. Journal of Biological Chemistry, 2017, 292, 19989-19998.	3.4	14
234	PEC-60 increases dopamine but not GABA release in the dorsolateral neostriatum of the halothane anaesthetized rat. An in vivo microdialysis study. Neuroscience Letters, 1994, 177, 53-57.	2.1	13

#	Article	IF	Citations
235	Lack of adenosine A1 and dopamine D2 receptor-mediated modulation of the cardiovascular effects of the adenosine A2A receptor agonist CGS 21680. European Journal of Pharmacology, 2004, 484, 269-275.	3.5	13
236	Revisiting the Functional Role of Dopamine D4 Receptor Gene Polymorphisms: Heteromerization-Dependent Gain of Function of the D4.7 Receptor Variant. Molecular Neurobiology, 2019, 56, 4778-4785.	4.0	13
237	Heterobivalent Ligand for the Adenosine A_{2A}â€"Dopamine D₂ Receptor Heteromer. Journal of Medicinal Chemistry, 2022, 65, 616-632.	6.4	13
238	Paraxanthine: Connecting Caffeine to Nitric Oxide Neurotransmission. Journal of Caffeine Research, 2013, 3, 72-78.	0.9	12
239	Luciferase complementation based-detection of G-protein-coupled receptor activity. BioTechniques, 2018, 65, 9-14.	1.8	12
240	Adenosine/dopamine receptor-receptor interactions in the central nervous system. Drug Development Research, 2001, 52, 296-302.	2.9	11
241	Comparison of Caffeine and d-amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary Paraxanthine. Journal of Addiction Research & Therapy, 2014, 05, 176.	0.2	11
242	Brain Iron Deficiency Changes the Stoichiometry of Adenosine Receptor Subtypes in Cortico-Striatal Terminals: Implications for Restless Legs Syndrome. Molecules, 2022, 27, 1489.	3.8	11
243	Preferential Gs protein coupling of the galanin Gal1 receptor in the Âµ-opioid-Gal1 receptor heterotetramer. Pharmacological Research, 2022, 182, 106322.	7.1	11
244	Motor depressant effects of systemically administered polyamines in mice: involvement of central NMDA receptors. European Journal of Pharmacology, 1996, 318, 231-238.	3.5	10
245	Adenosine A1-A2A Receptor Heteromer as a Possible Target for Early-Onset Parkinson's Disease. Frontiers in Neuroscience, 2017, 11, 652.	2.8	10
246	Detection of Receptor Heteromers Involving Dopamine Receptors by the Sequential BRET-FRET Technology. Methods in Molecular Biology, 2013, 964, 95-105.	0.9	10
247	Complexes of Ghrelin GHS-R1a, GHS-R1b, and Dopamine D₁Receptors Localized in the Ventral Tegmental Area as Main Mediators of the Dopaminergic Effects of Ghrelin. Journal of Neuroscience, 2022, 42, 940-953.	3.6	10
248	Modulation of [35S]GTPÎ³S binding to Chinese hamster ovary cell membranes by D2(short) dopamine receptors. Neuroscience Letters, 2000, 280, 135-138.	2.1	9
249	Akathisia and Restless Legs Syndrome. Sleep Medicine Clinics, 2021, 16, 249-267.	2.6	9
250	A Novel Class of Dopamine D₄ Receptor Ligands Bearing an Imidazoline Nucleus. ChemMedChem, 2016, 11, 1819-1828.	3.2	7
251	A trypsin inhibitor-like peptide PEC-60 reduces the affinity of dopamine D2 agonist binding sites in rat neostriatal membranes. European Journal of Pharmacology, 1991, 207, 365-366.	2.6	6
252	Heteromerization of G-Proteinâ€"Coupled Receptors. Implications for Central Nervous System Function and Dysfunction. Scientific World Journal, The, 2007, 7, 46-47.	2.1	6

#	Article	IF	Citations
253	Platforms for the identification of GPCR targets, and of orthosteric and allosteric modulators. Expert Opinion on Drug Discovery, 2010, 5, 391-403.	5.0	6
254	Heteromerization between Î±2A adrenoceptors and different polymorphic variants of the dopamine D4 receptor determines pharmacological and functional differences. Implications for impulsive-control disorders. Pharmacological Research, 2021, 170, 105745.	7.1	6
255	Adenosine A2A-dopamine D2 receptor heteromers operate striatal function: impact on Parkinson's disease pharmacotherapeutics. Neural Regeneration Research, 2018, 13, 241.	3.0	6
256	Reserpine potentiates NMDA-induced c-fos mRNA expression in the mouse brain. Neuroscience Letters, 1996, 212, 147-150.	2.1	5
257	Hormones and Neuropeptide Receptor Heteromers in the Ventral Tegmental Area. Targets for the Treatment of Loss of Control of Food Intake and Substance Use Disorders. Current Treatment Options in Psychiatry, 2017, 4, 167-183.	1.9	5
258	Evidence for the Existence of Antagonistic Intramembrane Adenosine A2a/dopamine D2 Receptor Interactions in the Basal Ganglia: Analysis from the Network to the Molecular Level. , 1995, , 499-507.		5
259	BHT-920 and LY-171555 (quinpirole) have similar affinities for striatal D-2 dopamine receptors, and similar affinities for striatal D-1 dopamine receptors. European Journal of Pharmacology, 1989, 166, 303-305.	3.5	4
260	The Adenosine Hypothesis of Restless Legs Syndrome. Journal of Caffeine and Adenosine Research, 2019, 9, 1-3.	0.6	4
261	Cellâ€type specific expression and behavioral impact of galanin and GalR1 in the locus coeruleus during opioid withdrawal. Addiction Biology, 2021, 26, e13037.	2.6	4
262	Targeting the equilibrative nucleoside transporter ENT1 in Huntington disease. Oncotarget, 2017, 8, 12550-12551.	1.8	4
263	Blocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia Disorders. , 2010, , 304-341.		4
264	L-dopa causes an acute, partial and reversible reversal of denervation-induced supersensitivity of striatal dopaminergic receptors. Psychopharmacology, 1987, 91, 254-6.	3.1	3
265	T-maze performance in rats following chronic neuroleptic treatment. Pharmacology Biochemistry and Behavior, 1990, 35, 481-484.	2.9	3
266	Prolonged treatment with haloperidol and clozapine in the rat: differential effects on spontaneous and theophylline-induced motor activity. Neuroscience Letters, 1997, 232, 21-24.	2.1	3
267	What Do You See as the Main Priorities, Opportunities, and Challenges in Caffeine Research in the Next Five Years?. Journal of Caffeine Research, 2011, 1, 5-12.	0.9	3
268	Dissecting striatal adenosineâ€cannabinoid receptor interactions. New clues from rats overâ€expressing adenosine A2A receptors. Journal of Neurochemistry, 2016, 136, 897-899.	3.9	3
269	Methylxanthines cause a decrease of prolactin plasma levels in healthy non-pregnant women. Human Psychopharmacology, 1989, 4, 33-39.	1.5	2
270	Bioluminescence Resonance Energy Transfer Assay to Characterize Giâ€Like G Protein Subtypeâ€Dependent Functional Selectivity. Current Protocols in Neuroscience, 2017, 81, 5.33.1-5.33.13.	2.6	2

#	ARTICLE	IF	CITATIONS
271	Adenosine Control of Striatal Functionâ€"Implications for the Treatment of Apathy in Basal Ganglia Disorders. , 2017, , 231-255.		2
272	What Is the Role of Adenosine Tone and Adenosine Receptors in Huntingtonâ€™s Disease?. , 2018, , 281-308.		2
273	Heteromerization of Adenosine and Dopamine Receptor Subtypes: Relevance for Neuronal Integration in Normal and Pathological States. Advances in Behavioral Biology, 2002, , 199-204.	0.2	2
274	The role of orexin and dopamine in sleep alterations from the progressive, neurotoxinâ€induced model of parkinsonism. FASEB Journal, 2010, 24, 300.7.	0.5	1
275	Role of Striatal A2A Receptor Subpopulations in Neurological Disorders. , 2013, , 179-197.		1
276	Sponsor's Foreword. Scientific World Journal, The, 2007, 7, 1-3.	2.1	0
277	Receptor Heteromerization. , 2014, , 91.		0
278	Allosterism Within GPCR Oligomers: Back to Symmetry. , 2017, , 433-450.		0
279	The Scope of Adenosine Signaling. Journal of Caffeine and Adenosine Research, 2018, 8, 1-2.	0.6	0
280	<i>Call for Papers:</i> Adenosine in Inflammation and Cancer. Journal of Caffeine and Adenosine Research, 2019, 9, 180-180.	0.6	0
281	Call for Papers: Adenosine in Inflammation and Cancer. Journal of Caffeine and Adenosine Research, 2020, 10, 41-41.	0.6	0
282	Call for Papers: Adenosine in the Central Nervous System. Journal of Caffeine and Adenosine Research, 2020, 10, 1-1.	0.6	0
283	Adenosine A2Aâ€cannabinoid CB1 receptor heteromers. Implications for the rewarding effects of cannabinoids. FASEB Journal, 2007, 21, A410.	0.5	0
284	NMDA-Induced Motor Activation in Rodents. , 1996, , 85-94.		0
285	Allosteric Mechanisms in the Adenosine A2A-Dopamine D2 Receptor Heteromer. Current Topics in Neurotoxicity, 2015, , 27-38.	0.4	0